Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMSHID LOTFI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1447447545
CMS profile
201350
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$250.93

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $250.93 9

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMSHID LOTFI

NPI 1447447545 · CMS profile ID 201350

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447447545?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMSHID LOTFI, NPI 1447447545, CMS profile ID 201350. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447447545?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMSHID LOTFI, NPI 1447447545, CMS profile ID 201350. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447447545?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMSHID LOTFI, NPI 1447447545, CMS profile ID 201350, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1447447545?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $250.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $28.4710/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200598069 CMS
Otsuka America Pharmaceutical, Inc. $16.5009/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227395936 CMS
ABBVIE INC. $27.4508/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202325873 CMS
Axsome Therapeutics, Inc. $33.9508/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235486653 CMS
Amneal Pharmaceuticals LLC $14.0507/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220541277 CMS
Amneal Pharmaceuticals LLC $23.1406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220541275 CMS
Novartis Pharmaceuticals Corporation $23.5105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200598061 CMS
Neurelis, Inc. $40.4402/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219194841 CMS
UCB, Inc. $43.4201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224533525 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $346.18 13
PY2020 $56.81 3
PY2021 $188.50 10
PY2022 $27.27 1
PY2025 $250.93 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,348,501.88 17
PY2024 Principal investigator $270,776.04 20
PY2023 Principal investigator $612,049.70 15
PY2022 Principal investigator $854,593.10 13
PY2021 Principal investigator $962,074.03 9
PY2020 Principal investigator $1,148,935.78 20
PY2019 Principal investigator $841,847.87 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 American Regent $23,569.50 12/12/2019 Non-covered Recipient Entity
Clinical Trials Network
1VIT15042 No dispute reported 06/30/2026 681797659
Principal investigator 1 Adamas Pharmaceuticals, Inc. $3,931.76 12/11/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694964747
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,193.04 12/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694964499
Principal investigator 1 Adamas Pharmaceuticals, Inc. $2,041.20 12/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694964503
Principal investigator 1 Biogen, Inc. $26,675.01 11/14/2019 Non-covered Recipient Entity
Clinical Trial Network
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 No dispute reported 06/30/2026 675309587
Principal investigator 1 Adamas Pharmaceuticals, Inc. $317.76 10/30/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694964199
Principal investigator 1 American Regent $11,064.80 10/25/2019 Non-covered Recipient Entity
Clinical Trials Network
1VIT15042 No dispute reported 06/30/2026 681797855
Principal investigator 1 Alkermes, Inc. $1,000.00 10/10/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 No dispute reported 06/30/2026 653528281
Principal investigator 1 Alkermes, Inc. $400.00 10/10/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 No dispute reported 06/30/2026 653528283
Principal investigator 1 Alkermes, Inc. $5,627.89 10/10/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 No dispute reported 06/30/2026 653528285
Principal investigator 1 Adamas Pharmaceuticals, Inc. $2,112.48 10/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694963773
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,032.96 09/11/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694963513
Principal investigator 1 Adamas Pharmaceuticals, Inc. $2,884.64 08/23/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694963321
Principal investigator 1 Alkermes, Inc. $1,064.70 08/19/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528279
Principal investigator 1 Adamas Pharmaceuticals, Inc. $253.44 08/14/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694963167
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,282.88 08/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694963049
Principal investigator 1 Adamas Pharmaceuticals, Inc. $5,512.56 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694962931
Principal investigator 1 Alkermes, Inc. $50.00 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528277
Principal investigator 1 American Regent $13,552.50 07/31/2019 Non-covered Recipient Entity
Clinical Trials Network
1VIT15042 No dispute reported 06/30/2026 681797551
Principal investigator 1 Adamas Pharmaceuticals, Inc. $708.32 07/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694962821
Principal investigator 1 Adamas Pharmaceuticals, Inc. $180.48 07/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694962825
Principal investigator 1 American Regent $6,500.00 07/23/2019 Non-covered Recipient Entity
Clinical Trials Network
1VIT15042 No dispute reported 06/30/2026 681797539
Principal investigator 1 American Regent $1,500.00 07/23/2019 Non-covered Recipient Entity
Clinical Trials Network
1VIT15042 No dispute reported 06/30/2026 681797541
Principal investigator 1 Alkermes, Inc. $9,055.80 07/17/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528275
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,193.04 07/05/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694962534
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,256.00 07/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694962397
Principal investigator 1 Adamas Pharmaceuticals, Inc. $100.00 06/19/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694962269
Principal investigator 1 Adamas Pharmaceuticals, Inc. $659.84 06/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694962089
Principal investigator 1 Alkermes, Inc. $50.00 06/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528273
Principal investigator 1 Alkermes, Inc. $161.63 05/28/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528271
Principal investigator 1 Adamas Pharmaceuticals, Inc. $3,553.44 05/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961959
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,032.96 05/22/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961842
Principal investigator 1 AbbVie, Inc. $10,800.00 05/14/2019 Non-covered Recipient Entity
Clinical Trial Network, LLC
M14-173 No dispute reported 06/30/2026 647569971
Principal investigator 1 Adamas Pharmaceuticals, Inc. $3,740.24 05/08/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694961601
Principal investigator 1 Adamas Pharmaceuticals, Inc. $4,490.16 05/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961401
Principal investigator 1 Adamas Pharmaceuticals, Inc. $602.88 04/17/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961195
Principal investigator 1 Adamas Pharmaceuticals, Inc. $5,512.56 04/17/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961199
Principal investigator 1 Adamas Pharmaceuticals, Inc. $253.44 04/17/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694961203
Principal investigator 1 Alkermes, Inc. $1,409.85 04/10/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528269
Principal investigator 1 AbbVie, Inc. $2,665.00 03/26/2019 Non-covered Recipient Entity
Clinical Trial Network, LLC
M14-173 No dispute reported 06/30/2026 647569969
Principal investigator 1 Alkermes, Inc. $76.26 03/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528267
Principal investigator 1 Alkermes, Inc. $1,409.85 03/13/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528265
Principal investigator 1 Adamas Pharmaceuticals, Inc. $16,157.68 03/06/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694960305
Principal investigator 1 Adamas Pharmaceuticals, Inc. $2,032.16 03/06/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694960313
Principal investigator 1 Adamas Pharmaceuticals, Inc. $4,503.28 03/06/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694960319
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,327.50 03/05/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED SUBCUTANEOUSLY VERSUS TERIFLUNOMIDE ADMINISTERED ORALLY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS No dispute reported 06/30/2026 640713969
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,300.00 03/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 640713973
Principal investigator 1 Adamas Pharmaceuticals, Inc. $18,130.00 02/20/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694959965
Principal investigator 1 Adamas Pharmaceuticals, Inc. $858.32 02/13/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT No dispute reported 06/30/2026 694959679
Principal investigator 1 Alkermes, Inc. $3,311.10 02/13/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528263
Principal investigator 1 Alkermes, Inc. $1,848.60 02/11/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528261
Principal investigator 1 Adamas Pharmaceuticals, Inc. $1,952.32 02/08/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694959663
Principal investigator 1 Alkermes, Inc. $50.00 02/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC.
A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 No dispute reported 06/30/2026 653528259
Principal investigator 1 Adamas Pharmaceuticals, Inc. $4,916.80 01/16/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694959385
Principal investigator 1 Adamas Pharmaceuticals, Inc. $18,198.24 01/16/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT No dispute reported 06/30/2026 694959389
Principal investigator 1 Biogen, Inc. $380,283.00 01/11/2019 Non-covered Recipient Entity
Clinical Trials Network
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease No dispute reported 06/30/2026 675310265
Principal investigator 1 Biogen, Inc. $26,864.00 01/03/2019 Non-covered Recipient Entity
Clinical Trials Network
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities No dispute reported 06/30/2026 675310267
Principal investigator 1 Novartis Pharmaceuticals Corporation $179,636.00 01/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK
A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA No dispute reported 06/30/2026 640713959